ArticleResearch square2023
Reaction hijacking inhibition of
Open access · greenAbstract readPreprint
In one paragraph
Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
44 authors at 18 institutions in 7 countries.
Stanley C XieDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.ORCID 0000-0001-7003-4677
Yinuo WangSchool of Pharmacy, University College London, London WC1N 1AX, United Kingdom.
Craig J MortonBiomedical Manufacturing Program, CSIRO, Clayton South, Australia.ORCID 0000-0001-5452-5193
Riley D MetcalfeCenter for Structural Biology, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Con DogovskiDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
Charisse Flerida A PasajeDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-9780-3680
Elyse DunnDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
Madeline R LuthDepartment of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Krittikorn KumpornsinParasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, CB10 1SA, United Kingdom.
Eva S IstvanDivision of Infectious Diseases, Department of Medicine, Washington University in St. Louis, USA.ORCID 0000-0002-8666-3248
Joon Sung ParkResearch Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.ORCID 0000-0002-1575-1849
Kate J FairhurstCenter for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Medical Center, New York, NY 10032, USA.
Nutpakal KetprasitDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.ORCID 0000-0001-8750-0187
Tomas YeoCenter for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Medical Center, New York, NY 10032, USA.ORCID 0000-0003-2923-6060
Okan YildirimChemical Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Mathamsanqa N BhebheSchool of Chemistry, University of Sydney, Camperdown, NSW 2006, Australia.
Dana M KlugSchool of Pharmacy, University College London, London WC1N 1AX, United Kingdom.
Peter J RutledgeSchool of Chemistry, University of Sydney, Camperdown, NSW 2006, Australia.ORCID 0000-0002-0767-5196
Luiz C GodoyDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Sumanta DeyDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Mariana Laureano De SouzaDepartment of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Jair L Siqueira-NetoDepartment of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Yawei DuDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
Tanya PuhalovichDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
Mona AminiDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
Gerry ShamiDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.ORCID 0000-0003-2094-1740
Duangkamon LoesbanluechaiParasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, CB10 1SA, United Kingdom.
Shuai NieMelbourne Mass Spectrometry and Proteomics Facility, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
Nicholas WilliamsonMelbourne Mass Spectrometry and Proteomics Facility, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.ORCID 0000-0002-2173-3452
Gouranga P JanaTCG Lifesciences Private Limited, Salt-lake Electronics Complex, Kolkata, India.
Bikash C MaityTCG Lifesciences Private Limited, Salt-lake Electronics Complex, Kolkata, India.
Patrick ThomsonSchool of Chemistry, The University of Edinburgh, Edinburgh EH9 3JJ, United Kingdom.ORCID 0000-0001-9831-9199
Thomas FoleySchool of Chemistry, The University of Edinburgh, Edinburgh EH9 3JJ, United Kingdom.
Derek S TanChemical Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-7956-9659
Jacquin C NilesDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-6250-8796
Byung Woo HanResearch Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.ORCID 0000-0001-7571-3791
Daniel E GoldbergDivision of Infectious Diseases, Department of Medicine, Washington University in St. Louis, USA.ORCID 0000-0003-3529-8399
Jeremy BurrowsMedicines for Malaria Venture, 20, Route de Pré-Bois 1215, Geneva 15, Switzerland.ORCID 0000-0001-8448-6068
David A FidockCenter for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Medical Center, New York, NY 10032, USA.ORCID 0000-0001-6753-8938
Marcus C S LeeParasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, CB10 1SA, United Kingdom.
Elizabeth A WinzelerDepartment of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Michael D W GriffinDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.ORCID 0000-0001-9845-7735
Matthew H ToddSchool of Pharmacy, University College London, London WC1N 1AX, United Kingdom.ORCID 0000-0001-7096-4751
Leann TilleyDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.ORCID 0000-0001-9910-0199
The University of Melbourne · AUThe University of Sydney · AUUniversity of California San Diego · USColumbia University Irving Medical Center · USMemorial Sloan Kettering Cancer Center · USSeoul National University · KRMassachusetts Institute of Technology · USTCG Lifesciences (India) · INWashington University in St. Louis · USBiotechnology Institute · USCommonwealth Scientific and Industrial Research Organisation · AUCSIRO Manufacturing · AUIndian Institute of Chemical Biology · INScripps Research Institute · USUniversity College London · GBUniversity of Dundee · GBUniversity of Edinburgh · GBWellcome Sanger Institute · GB
Funding
Training Program in Basic Clinical GeneticsT32GM008666 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAMILTON, BRUCE A · 1998 to 2021
$8.6MDiscovery of long-acting, chemoprotective antimalarial compoundsR01AI152533 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WINZELER, ELIZABETH A · 2020 to 2024
$3.5MNIAID NIH HHS R01 AI152533NIGMS NIH HHS T32 GM008666Wellcome Trust
Abstract
Malaria poses an enormous threat to human health. With ever increasing resistance to currently deployed drugs, breakthrough compounds with novel mechanisms of action are urgently needed. Here, we explore pyrimidine-based sulfonamides as a new low molecular weight inhibitor class with drug-like physical parameters and a synthetically accessible scaffold. We show that the exemplar, OSM-S-106, has potent activity against parasite cultures, low mammalian cell toxicity and low propensity for resistance development.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.